magnims.eu)), to mirror their proposal 2 to treat symptomatic lesions in the brainstem and spinal cord similar to asymptomatic lesions-a proposal that was included in the 2017 revisions. 1 The line of reasoning of the MAGNIMS group was that there was no fundamental reason to treat the (symptomatic) lesion in the optic nerve (a classical site of involvement) differently than a brainstem or cord lesion. 2 In this issue of Multiple Sclerosis Journal (MSJ), the pros 3 and cons 4 of doing so are elaborated by debaters who, in the end, do not differ much in their conclusion. Ultimately, their answers are "YES, but" and "NOT, yet." Such a paradox is a reflective of good science where the dialectics of arguments should stimulate both those who propose and refute the hypothesis to examine the evidence in favor and against it. In fact, both camps conclude that more data are needed for what essentially is a logical, next step for the next version of the McDonald criteria.
The current evidence collected by the MAGNIMS group 5 was designated by the International Panel as too preliminary, despite showing a promising increase in sensitivity. The main concern of the panel was the reduced specificity, which may simply reflect the lack of long enough follow-up to ascertain late converters. However, even when all the abnormal cases do convert and specificity is good, it may signify a better prognosis for patients who present with ON and a few brain magnetic resonance imaging (MRI) lesions only. 6 Although not a diagnostic issue per se, this does convey a different prognosis and treatment implications. The discussion was muddied when going beyond MRI evidence as both camps agree that more standardization and normative data are needed for optical coherence tomography (OCT) and visual evoked potential (VEP).
Essential data that are missing are a prospective study of all types of clinically isolated syndrome (CIS) patients (not just ON) with a systematic examination of the optic nerve, including MRI, OCT, and VEP. Other issues that need to be addressed include standardization of these techniques, provision of normative data, and differentiation from neuromyelitis optica (NMO). The MAGNIMS group has already embarked on such a study in Europe, and hopefully, others will contribute to the evidence base to give the optic nerve a more just place in the next iteration of the McDonald criteria.
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